| Primary |
|
| Renal Impairment |
66.7% |
| Hepatic Enzyme Increased |
33.3% |
|
| Secondary |
| Product Used For Unknown Indication |
58.6% |
| Drug Use For Unknown Indication |
9.9% |
| Pain |
4.8% |
| Analgesic Therapy |
2.7% |
| Phantom Pain |
2.6% |
| Pyrexia |
2.6% |
| Hypertension |
2.3% |
| Laparoscopy |
2.0% |
| Back Pain |
1.7% |
| Gastric Cancer |
1.6% |
| Rheumatoid Arthritis |
1.6% |
| Nausea |
1.4% |
| Acute Promyelocytic Leukaemia |
1.3% |
| Prophylaxis Against Gastrointestinal Ulcer |
1.3% |
| Type 2 Diabetes Mellitus |
1.2% |
| Prophylaxis |
1.0% |
| Multiple Drug Overdose |
0.9% |
| Trigeminal Neuralgia |
0.9% |
| Arthritis |
0.8% |
| Coronary Artery Disease |
0.8% |
|
| Agranulocytosis |
17.2% |
| Toxic Epidermal Necrolysis |
10.1% |
| Kounis Syndrome |
7.1% |
| Renal Failure |
7.1% |
| Transaminases Increased |
6.1% |
| Lip Oedema |
5.1% |
| Pancytopenia |
5.1% |
| Pancreatitis |
4.0% |
| Pyrexia |
4.0% |
| Stevens-johnson Syndrome |
4.0% |
| Suicide Attempt |
4.0% |
| Vomiting |
4.0% |
| Wound Infection |
4.0% |
| Death |
3.0% |
| Stomatitis |
3.0% |
| Suicidal Ideation |
3.0% |
| Urine Porphobilinogen Increased |
3.0% |
| Acute Febrile Neutrophilic Dermatosis |
2.0% |
| Depressed Level Of Consciousness |
2.0% |
| Drug Interaction |
2.0% |
|
| Concomitant |
| Product Used For Unknown Indication |
17.6% |
| Pain |
16.4% |
| Drug Use For Unknown Indication |
10.2% |
| Hypertension |
9.0% |
| Rheumatoid Arthritis |
5.7% |
| Renal Failure Chronic |
4.0% |
| Prophylaxis |
3.9% |
| Non-small Cell Lung Cancer |
3.9% |
| Prostate Cancer |
3.7% |
| Multiple Myeloma |
3.6% |
| Back Pain |
3.4% |
| Thrombosis Prophylaxis |
2.8% |
| Nausea |
2.7% |
| Chronic Obstructive Pulmonary Disease |
2.2% |
| Osteoporosis |
2.1% |
| Hiv Infection |
2.0% |
| Depression |
1.8% |
| Pneumonia |
1.7% |
| Constipation |
1.7% |
| Diabetes Mellitus |
1.7% |
|
| Vomiting |
9.7% |
| Sepsis |
8.0% |
| Renal Failure |
7.2% |
| Hepatic Enzyme Increased |
6.8% |
| Fatigue |
5.9% |
| Pain |
5.9% |
| Pneumonia |
5.1% |
| Respiratory Failure |
5.1% |
| Rhabdomyolysis |
4.6% |
| Narcotic Intoxication |
4.2% |
| Somnolence |
4.2% |
| Syncope |
4.2% |
| Death |
3.8% |
| Nausea |
3.8% |
| Oedema Peripheral |
3.8% |
| Transaminases Increased |
3.8% |
| Urinary Tract Infection |
3.8% |
| Anal Fissure |
3.4% |
| Pyrexia |
3.4% |
| Tachycardia |
3.4% |
|
| Interacting |
| Product Used For Unknown Indication |
53.8% |
| Pain |
19.2% |
| Heart Transplant |
7.7% |
| Plasma Cell Myeloma |
7.7% |
| Cardiomyopathy |
3.8% |
| Cardiovascular Event Prophylaxis |
3.8% |
| Hypertension |
3.8% |
|
| Wound Infection |
50.0% |
| Cardio-respiratory Arrest |
25.0% |
| Drug Interaction |
25.0% |
|
